Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.
The American Academy of Allergy, Asthma, and Immunology / World Allergy Organization (AAAAI/WAO) 2025 Joint Congress took place from February 28 to March 3 in San Diego, where leading experts explored progress in developing effective treatments for allergy and immunologic care. This premier event offered transformative educational sessions, groundbreaking research presentations, and ample networking opportunities to advance the field of allergy and immunology. This year’s meeting was filled with exciting sessions on topics such as the consensus statement redefining anaphylaxis, optimal management of urticaria, and innovative therapeutic strategies for hereditary angioedema. Attendees also heard updates on key studies, including the three-stage OUtMATCH trial, which compared omalizumab with oral immunotherapy, and the phase 3 PEOPLE study, which evaluated the long-term effects of epicutaneous immunotherapy in peanut allergy.
Ruchi Gupta, MD, MPH
Professor, Director, Center for Food Allergy and Asthma Research, Department of Pediatrics and Medicine, Northwestern University Feinberg School of Medicine; Clinical Attending, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, Illinois
“What was really interesting for me is just to see how much is in the pipeline. There are many other biologics and oral medications that are being developed for CSU, and also for allergies, food allergies, and anaphylaxis…. Coming to this meeting always gives you that hope again…we have a lot of things to look forward to.”
Preconference Considerations
AAAAI/WAO 2025: Previewing Advances in Allergy Treatment
Dr Gupta looks ahead to the upcoming AAAAI/WAO conference, bringing together global researchers and clinicians to advance allergy science. She is particularly interested in recent advances in anaphylaxis, angioedema, and urticaria, including new treatments such as nasal epinephrine, age-specific epinephrine formulations, and emerging biologics and looks forward to learning more about these developments and sharing cutting-edge knowledge to improve patient care.
Quick Clinical Takeaways
AAAAI/WAO 2025: Updates in Anaphylaxis, Angioedema, and CSU
Dr Gupta attended the 2025 AAAAI/WAO meeting in San Diego, highlighting new insights into anaphylaxis, angioedema, and urticaria. A key highlight was the consensus statement refining the definition of anaphylaxis for improved clarity for providers and patients. Also, emerging biologics for the treatment of urticaria were discussed. Dr Gupta found the event inspiring, showcasing remarkable progress in allergy and immunology care.
How Will My Patients Benefit?
AAAAI/WAO 2025: The Impact of Advancements in Allergy Care
Back from the 2025 AAAAI/WAO Joint Congress, Dr Gupta highlights advances in CSU treatment, including early biologic use. Dr Gupta also discusses progress in food allergy therapies, such as oral immunotherapy for peanut allergy, omalizumab for multi-food allergies, and new epinephrine options like nasal spray and sublingual formulations.
Polling Question
Summary
The 2025 AAAAI/WAO Joint Congress in San Diego brought together experts to discuss groundbreaking advancements in allergy and immunology care. In a series of three videos, Dr Ruchi Gupta highlighted key updates, including a new consensus statement redefining anaphylaxis for improved clinical clarity and emerging biologics for CSU. Dr Gupta also explored progress in food allergy treatments, such as oral immunotherapy for peanut allergy, omalizumab for multi-food allergies, and new epinephrine delivery options like nasal spray and sublingual formulations. Overall, she found the meeting inspiring, showcasing significant strides in patient care and treatment innovation.
Resources
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
